Telomir Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Legal Proceedings
Item 1. Legal Proceedings
From time to time, we may become involved in legal proceedings, claims, investigations and other matters arising in the ordinary course of our business. Except as described below, we are not currently a party to any material pending legal proceeding.
On June 5, 2026, a complaint was filed by the Estate of Christopher Columbus Chapman, Jr., a former Chief Executive Officer of the Company, in the circuit court of Miami-Dade County, Florida claiming that the Company failed to timely transfer restricted common stock of the Company. The Company subsequently had the case transferred to the Complex Business Litigation Division of the Circuit Court of Miami-Dade County, Florida. The plaintiff claims damages in excess of $3.5 million due to the delays in transfer. The Company believes the plaintiff’s position is without merit and intends to vigorously defend itself.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.